Milliken S T, Tattersall M H, Woods R L, Coates A S, Levi J A, Fox R M, Raghavan D
Clinical Oncology Department, Royal North Shore Hospital, Sydney, Australia.
Eur J Cancer Clin Oncol. 1987 Nov;23(11):1645-8. doi: 10.1016/0277-5379(87)90443-3.
Of 101 patients with symptomatic adenocarcinoma or undifferentiated carcinoma of unknown primary site, 95 were evaluable for the effects of two randomized chemotherapy regimens. Forty-eight patients received combination doxorubicin and mitomycin C (DM) and 47 received combination cisplatin, vinblastine and bleomycin (PB). Response rates were not significantly different between the two treatment groups, 42% for DM and 32% for PVB, with an overall response rate of 37.1%. Survival differences for DM and PVB treated groups were not significantly different, with 18 weeks and 25 weeks median survivals respectively. Toxicities were unequal for the two treatment groups with increased haematological toxicity for DM and greater gastrointestinal toxicity for PVB. The authors conclude both therapies were of limited efficacy in the treatment of ACUP patients and emphasize that only symptomatic patients should be considered for such therapies.
在101例有症状的原发性不明的腺癌或未分化癌患者中，95例可评估两种随机化疗方案的疗效。48例患者接受多柔比星与丝裂霉素C联合治疗（DM），47例患者接受顺铂、长春碱与博来霉素联合治疗（PVB）。两个治疗组的缓解率无显著差异，DM组为42%，PVB组为32%，总缓解率为37.1%。DM组和PVB组的生存差异无显著差异，中位生存期分别为18周和25周。两个治疗组的毒性不同，DM组血液学毒性增加，PVB组胃肠道毒性更大。作者得出结论，两种疗法在治疗原发性不明的腺癌患者中疗效有限，并强调仅应对有症状的患者考虑此类疗法。
